Affordable Access

Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.

Authors
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
Volume
9
Issue
4
Pages
1354–1360
Identifiers
PMID: 12684404
Source
Medline
License
Unknown

Abstract

CIFN was safely administered s.c. three times weekly at doses up to 15.0 microg/m(2). Although there were no responses, the median survival was longer than expected in a previously treated patient population with metastatic RCC.

Statistics

Seen <100 times